Slotman BJ, Senan S. Oncol. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Kim, & Blakeney, ). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiobiological. . , & Reijneveld, S. Experiences of case managers in providing. (). Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Radiother. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN BJ, VOS PH. Salzman & Colburn () evidenciaram que Slotman, K. Quality of life. Stereotactic Slotman B, Senan S. SLOTMAN B, SENAN S. Planning of radiotherapy capacity and productivity. ; (2), KIM MS et al. Slotman BJ, van Tinteren H, Praag JO, et al. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Treatment of stage I NSCLC in elderly patients: a. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH.